Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reprotect Buffergel polyacrylic gel contraceptive's vaginal irritation rate studied by NIAID.

This article was originally published in The Tan Sheet

Executive Summary

BUFFERGEL CONTRACEPTIVE NIAID/HIVNET U.S. PHASE I CLINICAL TRIAL will be completed in September, Buffergel owner Reprotect of Baltimore, Md., said. The company owns the rights to market the polyacrylic acid gel upon which Buffergel is based; the gel was created by company founders Richard Cone, PhD, and Kevin Whaley, PhD, Johns Hopkins University, and Thomas Moench, MD, formerly with Hopkins, now medical director of Reprotect. The National Institute of Allergy & Infectious Diseases, through its HIVNET international HIV research network, is interested in the product as a possible prophylaxis against transmission of human immunodeficiency virus.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087253

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel